Wed, Apr 23, 2014, 10:10 AM EDT - U.S. Markets close in 5 hrs 50 mins

Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pennywise6678 pennywise6678 Jun 12, 2005 11:32 AM Flag

    mildly interesting

    TC

    At the bottom of that Motley Fool article, it has the following disclaimer:

    --> This commentary was originally published on Feb. 4, 2005. It has been updated.

    Fool writer Paul Elliott owns shares of ImClone, but no other company mentioned. Dell, Schwab, and Biogen Idec are Motley Fool Stock Advisor recommendations. The Motley Fool has a full disclosure policy. <--

    But---even though MF did not make an actual recommendation on SCLN, I believe other stock screening services have been recommending it based on the incredible inside buys and the extreme oversold situation this past Spring. For example, this stock originally came up as a "buy" on my stock screener at $3.45 this spring (before the drop to $2.10). I watched it based on the initial recommendation as it tested $3.00, then started buying in. By the way, before anyone thinks I'm too smart/lucky: I tried to average down with this one based on the Cavazza buying, but as it swooned through the $2s I got scared and stopped buying at $2.50. I could just kick myself now for not buying it all the way down, but at the time it felt like I was staring into the abyss!

    I've been lurking here for a while, and the informative posts with all the wonderful research links posted by Bertha and thoughtful situational analysis gave me food for thought, and help me to become a "Z" believer.

    Soooo...TC, Sno, GMBart, Randal, Doc, Bertha etc etc etc--thanks for being so very informative (and entertaining!).

    -Penny

 
SCLN
4.62-0.090(-1.91%)10:09 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.